Randomized trial · people

NMN (MIB-626) raised blood NAD levels in older adults over 14 days

Checked against the paper Randomized trialPublished by PepVault

The takeaway

This trial shows that this specific pharmaceutical-grade NMN raised blood NAD in older adults over 14 days, with more NAD at the higher dose, but it does not show any health benefit.

Kind
Randomized trial
Studied in
People
Number studied
32
Published
2023
Journal
J Gerontol A Biol Sci Med Sci

What they tested

The team tested how MIB-626, an oral form of NMN (nicotinamide mononucleotide), moves through the body and how it changes blood NAD and related compounds.

How the study was done

A double-blind, placebo-controlled randomized trial in 32 overweight or obese adults aged 55-80. They took 1 000 mg of MIB-626 once daily, 1 000 mg twice daily, or a placebo (a dummy pill) for 14 days, and blood NMN, NAD and related compounds were measured with liquid chromatography-tandem mass spectrometry, a lab method for measuring compounds.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking NAD+? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

On day 14, blood NMN was higher in both MIB-626 groups than in the placebo group. Measured as total exposure over the sampling period (mean AUClast), blood NMN was 1.7-times above baseline in the once-daily arm and 3.7-times above baseline in the twice-daily arm. Blood NAD rose substantially, and the rise was larger at the higher dose. NAD-related compounds were higher on days 8 and 14 than at baseline, very little unchanged NMN showed up in urine, and side effects were about as common as on placebo.

What it doesn’t show

This was a small, 14-day trial in overweight or obese adults aged 55-80, so it does not show long-term safety or how other groups respond. It measured blood levels of NMN and NAD, not health outcomes like strength, weight or disease.

The paper

Pencina et al. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. J Gerontol A Biol Sci Med Sci. 2023.

The compounds

More studies on NAD+

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking NAD+? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo